Particle.news
Download on the App Store
5 ARTICLES
·
last yr.

Gold Nanocrystals Show Promise in Treating MS and Parkinson's

Phase 2 clinical trials reveal significant improvements in brain energy metabolites, offering hope for neurodegenerative disease treatments.

Image
Clinical trials using orally administered gold nanoparticles produced promising results in treating neurodegenerative diseases
Image
Gold nanocrystals suspended in a water buffer represent a novel therapeutic agent developed by Clene Nanomedicine for neurodegenerative conditions. This nanomedicine, called CNM-Au8, is being investigated to treat patients with multiple sclerosis and Parkinson’s disease in clinical trials at UT Southwestern.( credit: Random 42/Source: Clene Nanomedicine)

Overview

  • Orally administered gold nanocrystals have shown promising results in treating multiple sclerosis (MS) and Parkinson's disease (PD), improving crucial brain energy metabolites.
  • The treatment, known as CNM-Au8, targets the brain's energy metabolism by enhancing the NAD+/NADH ratio, a key indicator of brain energy capacity.
  • Participants in the trials experienced a statistically significant increase in the NAD+/NADH ratio, with an average improvement of 10.4% after 12 weeks of treatment.
  • In Parkinson's disease patients, the treatment led to significant improvements in 'motor experiences of daily living,' suggesting functional benefits.
  • The research supports advancing to larger phase 3 trials to further test the treatment's efficacy, with ongoing enrollment for participants with progressive MS.